Message delivered — with a punch to the face.
Earlier this week, Richard Pazdur, the Food and Drug Administration’s top cancer drug regulator, told STAT that he intended to use an upcoming advisory meeting to make clear to U.S. drug companies that data from cancer clinical trials conducted entirely in China would not be sufficient for approval here.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
